New York, July 17, 2023 (GLOBE NEWSWIRE) -- Global Breast Cancer Liquid Biopsy Market size accounted for USD 0.4 Bn in 2022. It is projected to surpass around USD 2.7 Bn by 2032, and it is poised to reach a CAGR of 22.6% from 2023 to 2032.
Breast cancer liquid biopsy is referred to as a diagnostic technique that was used to detect and analyze the genetic material from breast cancer cells circulating in the blood or other body fluids, and it is the best substitute for traditional tissue biopsies, which is non-invasive and involves the removal of a sample of the tumor or affected tissue for analysis.
Get additional highlights on major revenue-generating segments, Request a Breast Cancer Liquid Biopsy Market sample report at: https://marketresearch.biz/report/breast-cancer-liquid-biopsy-market/request-sample
Key Takeaway
- By Biomarker Type, the circulating tumor cells (CTCs) segment has dominated the market, and it is growing at the highest CAGR over the forecast period 2023 to 2032.
- By Application, the diagnosis segment accounted for the majority of the market share.
- In 2022, North America dominated the market with the highest revenue share of 34.2%.
- Asia-Pacific will grow at a significant revenue share of 22.7% from 2023-2032.
Liquid biopsy for breast cancer helps in discovering the cancer-specific biomarkers hidden within one's bodily fluids. The major factor that drives the growth of the breast cancer liquid biopsy market is the advantages of this method over the traditional biopsy methods. Furthermore, the other factors which propel the market growth are increasing focus on precision medicines, increasing incidence of cancer, and others.
Factors Affecting the Growth of the Breast Cancer Liquid Biopsy Market
There are several factors that can affect the growth of the global Breast Cancer Liquid Biopsy Market. Some of these factors include:
- Increasing Incidence of Breast Cancer: The increasing incidence of breast cancer and its early detection drives the growth of the market.
- Technological Advancements: Various technological advancements, like PCR and next-generation sequencing, influence the growth of the market.
- Advantages over Traditional Biopsy Methods: Breast cancer liquid biopsy has several advances over the traditional biopsy method. This has fueled the demand for this method.
- Increasing R&D Initiatives: Numerous R&D are carried out to improve the efficiency of the method. This will likely propel the growth of the market over the forecast period.
To understand how our report can bring a difference to your business strategy, Inquire about a brochure at https://marketresearch.biz/report/breast-cancer-liquid-biopsy-market/#inquiry
Top Trends in Global Breast Cancer Liquid Biopsy Market
Growing Demand
Worldwide, breast cancer is one of the leading causes of cancer-related fatalities in women. Liquid biopsy has developed in recent years as a promising diagnostic instrument for the disease due to its numerous advantages over conventional biopsy methods. In the upcoming years, the global breast cancer liquid biopsy market is projected to expand at an impressive CAGR because of a number of market trends.
Market Growth
Non-invasive liquid biopsy tests are another important trend influencing the liquid biopsy market for breast cancer. These tests can be conducted with a direct blood draw, eliminating the need for invasive biopsy techniques. Compared to conventional biopsy methods, non-invasive liquid biopsy tests are less painful, less expensive, and have a lower risk of complications.
Regional Analysis
North America held the largest market share of, 34.2% of the overall market. In women, breast cancer is one of the major cancer-related causes of death. Liquid biopsy is one of the most effective early detection methods for breast cancer. The liquid biopsy for breast cancer has revolutionized the early detection and diagnosis of cancer.
Breast cancer liquid biopsy is a non-invasive diagnostic technique that uses blood samples to detect genetic mutations and proteins linked to the disease. A liquid biopsy can detect breast cancer at an early stage, and this improves the patient's survival chances. Liquid biopsy is a less invasive and more sensitive breast cancer diagnostics instrument than traditional methods such as mammography.
Competitive Landscape
Companies that manufacture, develop, and sell liquid biopsy tests for the detection of breast cancer are the leading players in the breast cancer liquid biopsy market. For instance, Thermo Fisher Scientific offers the Oncomine Dx Target Test, an FDA-approved comprehensive genomic profiling test for solid tumors. The Elecsys CEA immunoassay test manufactured by Roche aids in monitoring the progression of breast cancer treatment. Also, Illumina offers TruSight Oncology 500, a next-generation sequencing (NGS) test that detects genetic mutations in solid tumors.
Make informed business decisions with our sample report, revealing key market insights Click Here To Download/Request a Sample
Scope of Report
| Report Attribute | Details |
| Market Value (2022) | USD 0.4 Bn |
| Market Size (2032) | USD 2.7 Bn |
| CAGR (from 2023 to 2032) | 22.6% |
| North America Revenue Share | 34.2% |
| Asia-Pacific Revenue Share | 22.7% |
| Historic Period | 2016 to 2022 |
| Base Year | 2022 |
| Forecast Year | 2023 to 2032 |
Market Drivers
Growing Demand for Liquid Biopsy
The incidences of breast cancer are on the rise worldwide. This has led to a growing demand for non-invasive diagnostic tests, such as liquid biopsies, for early cancer detection. By providing high sensitivity and specificity coupled with a less invasive approach, advances in liquid biopsy technologies facilitate this requirement.
Market Restraints
Cost Barriers Liquid Breast Biopsy
Several factors are restraining the growth of the breast cancer liquid biopsy market, including the high cost of liquid biopsy tests, the lack of standardization in liquid biopsy procedures, the limited accuracy of liquid biopsy tests compared to traditional biopsies, the challenge of finding trained professionals to perform liquid biopsy tests and regulatory and reimbursement issues.
Market Opportunities
Liquid Biopsy Revolutionizes Breast Cancer Diagnosis
Breast cancer remains a significant global public health challenge, with millions of women diagnosed each year. Nowadays, breast cancer patients have more hope than ever before because of the diagnostic and treatment options that are more advanced than ever before. The use of liquid biopsy as a diagnostic treatment represents a market segment with significant growth potential for breast cancer. Technological advances and increased R&D have smoothened the way for precision medicine, which provides personalized treatments based on an individual's genetic composition.
Maximize your profitability with MarketResearch.Biz - Gain a competitive edge by acquiring this premium report at https://marketresearch.biz/purchase-report/?report_id=24573
Report Segmentation of the Breast Cancer Liquid Biopsy Market
Biomarker Type Insight
The Circulating Tumor Cells (CTCs) Held the Maximum Revenue Share
The segment of CTCs dominates the breast cancer liquid biopsy market. CTCs are bloodstream cancer cellsThe detection of CTCs in blood samples is a non-invasive method for monitoring cancer progression and predicting a patient's treatment response. Because of the economic growth in developing economies, CTCs are being used more frequently in the breast cancer liquid biopsy market.
In emerging countries, the cost of healthcare is high, which makes it difficult for many people to get healthcare. However, economic growth makes healthcare more affordable and accessible in rising economies. The increase in disposable income has augmented the demand for quality cancer diagnosis and treatment, among other medical services.
Application Insight
The Diagnosis Segment Accounted for the Maximum Revenue Share
The diagnosis segment dominated the market with the highest revenue share. The diagnosis of cancer is the initial step in developing an effective treatment plan. Traditional biopsy techniques possess invasive, often painful, and expensive procedures. The liquid biopsy is a non-invasive method of diagnosing malignancy.
The adoption of liquid biopsy procedures for the diagnosis of breast cancer is increasing due to the economic growth in developing economies. In developed countries, the cost of healthcare is expensive, which makes it difficult for many people to get healthcare. However, economic growth makes healthcare more affordable and accessible in increasing economies.
Uncover valuable statistics and future projections by accessing a sample report for historical and forecast market data spanning 2016 to 2032 at https://marketresearch.biz/report/breast-cancer-liquid-biopsy-market/request-sample
Market Segmentation
By Biomarker Type
- Circulating Tumor Cells (CTCs)
- Cell-free DNA (cfDNA)
- Extracellular Vesicles (EVs)
- Other Circulating Biomarkers (ctRNA, cfRNA, and cell-free proteins)
By Application
- Early Detection/Screening
- Diagnosis
- Treatment Selection
- Monitoring
Key Regions
- North America
- The US
- Canada
- Mexico
- Western Europe
- Germany
- France
- The UK
- Spain
- Italy
- Portugal
- Ireland
- Austria
- Switzerland
- Benelux
- Nordic
- Rest of Western Europe
- Eastern Europe
- Russia
- Poland
- The Czech Republic
- Greece
- Rest of Eastern Europe
- APAC
- China
- Japan
- South Korea
- India
- Australia & New Zealand
- Indonesia
- Malaysia
- Philippines
- Singapore
- Thailand
- Vietnam
- Rest of APAC
- Latin America
- Brazil
- Colombia
- Chile
- Argentina
- Costa Rica
- Rest of Latin America
- Middle East & Africa
- Algeria
- Egypt
- Israel
- Kuwait
- Nigeria
- Saudi Arabia
- South Africa
- Turkey
- United Arab Emirates
- Rest of MEA
Market Key Players
- QIAGEN N.V.
- Roche Diagnostics
- Bio-Rad Laboratories
- Myriad Genetics
- Biocept, Qiagen
- Hoffmann-La Roche AG
- Menarini Silicon Biosystems
- Illumina
- Cynvenio Biosystems Inc.
- Genomic Health Inc.
- Thermo Fisher Scientific Inc.
- Fluxion Biosciences Inc.
- Biodesix Inc.
- Guardant Health Inc.
- Isogen Life Science B.V.
- Other Key Players
Recent Development of the Breast Cancer Liquid Biopsy Market
- In August 2021, NeoGenomics acquired Inivata, a move that is anticipated to strengthen its position in the oncology market.
- In May 2021, Guardant Health announced positive results from a clinical trial of Guardant360 for detecting breast cancer recurrence.
- In February 2021, For the purpose of identifying patients with metastatic breast cancer who may benefit from targeted therapies, Biodesix launched GeneStrat.
- In November 2020, Qiagen launched a liquid biopsy panel for breast cancer with biomarkers for detecting mutations and fusions in disease-related genes.
- In September 2020, Using AI, genomics, and liquid biopsy to identify cancer signals in the blood, Freenome's liquid biopsy test demonstrated high sensitivity and specificity in detecting early-stage breast cancer.
Browse More Related Reports
- Cancer Biomarkers Market size is expected to be worth around USD 67.1 Bn by 2032 from USD 23.9 Bn in 2022, growing at a CAGR of 11.2% during the forecast period from 2023 to 2032.
- Cancer Care Market size is expected to be worth around USD 437.8 Bn by 2032 from USD 185.6 Bn in 2022, growing at a CAGR of 9.2% during the forecast period from 2023 to 2032.
- Liquid Biopsy Market was valued at USD 2.4 billion in 2021 & is projected to reach USD 9.7 billion by 2027. It is expected to grow at an 28.9% CAGR between 2021 and 2027.
- Diagnostic Tests Market size is expected to be worth around USD 410.5 Bn by 2032 from USD 182.0 Bn in 2022, growing at a CAGR of 8.7% during the forecast period from 2023 to 2032.
About Us:
MarketResearch.Biz (Powered by Prudour Pvt Ltd) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report-providing firm. MarketResearch.Biz provides customization to suit any specific or unique requirement and tailor-makes reports as per request. We go beyond boundaries to take analytics, analysis, study, and outlook to newer heights and broader horizons.
Follow Us on LinkedIn: https://www.linkedin.com/company/marketresearch-biz/
Follow Us on Facebook: https://www.facebook.com/marketresearch.biz
Follow Us on Twitter: https://twitter.com/PrudourResearch
